Key statistics dashboard for Hepion Pharmaceuticals, Inc. (HEPA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease.
Stock Data
| Price | $0.07 |
| Market Cap | $1M |
| Enterprise Value | -$825209 |
| Exchange | OTC |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.28 |
| Price / Book | 0.88 |
| P/S | 0.00 |
| EV/EBITDA | 0.29 |
| EV/Sales | 0.00 |
| EV/FCF | 0.52 |
| P/FCF | -0.51 |
| Earnings Yield | -285.36% |
| FCF Yield | -198.42% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -139.73% |
| Return on Assets | -165.42% |
| Return on Invested Capital | -219.39% |
| Return on Capital Employed | -219.39% |
Financial Health
| Current Ratio | 3.91 |
| Quick Ratio | 3.91 |
| Cash Ratio | 3.31 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.57 |
| Interest Coverage | -137.92 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -114.78 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.08 |
| Cash per share | 0.10 |
| FCF per share | -0.10 |
| Tangible Book Value per share | 0.08 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.33 |
Related companies: CDT · COCH · ENVB · LIXT · NIVF · PTPI · SRZN
Explore sector: Healthcare · Biotechnology
More sections of HEPA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks